Clinicopathological importance of survivin immunoexpression in reproductive age patients with serous borderline ovarian tumors
Abstract
Purpose: The aim of the present study was to evaluate survivin immunoexpression and the clinicopathologic correlations in serous borderline ovarian tumors (BOT) patients ≤ 40 years old.
Materials and Methods: A total of 36 BOT cases were evaluated. After excluding the mucinous type and patients over 40 years of age, 20 serous BOT cases meeting the criteria were included. A similar number of benign ovarian cysts and 20 serous malign ovarian tumors were randomly included as the control group. The patients were then staged based on their surgical findings and 2014 FIGO criteria, and their histological tumor types obtained from pathological specimens were determined using WHO criteria. The survivin levels in the specimens were analyzed using immunohistochemical assays.
Results: Positive survivin expression was detected in 10% of benign tumors, 100% of serous BOTs, and 100% of serous malign ovarian tumors. Mean survivin immunoreactivity was statistically similar between groups and it was found to be significantly higher in both groups compared to the control group. Survivin expression was positively correlated with FIGO stage, tumor grade, microinvasion, and micropapillary pattern.
Conclusion: Survivin immunoexpression is correlated with the malignancy potential of serous BOTs, and that survivin immune expression may be a histopathological marker that will help in making a decision on fertility-sparing surgery and follow upin young patients.
Keywords
Serous borderline ovarian tumors , Survivin , Fertility-sparing surgery
Kaynakça
- 1. Hauptmann S, Friedrich K, Redline R, et al. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125-42.
- 2. Trillsch F, Ruetzel JD, Herwig U, et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (borderline ovarian tumor). J Ovarian Res. 2013;6:48.
- 3. Ureyen I, Karalok A, Tasci T, et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol Cancer. 2016;26:66-72.
- 4. Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014;24:S5-S8.
- 5. Helpman L, Beiner ME, Aviel-Ronen S, et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015;104:138-44.
- 6. Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer research. 2007;27(4c):2803±8. Epub 2007/ 08/19. PMID: 17695451.
- 7. He X, Yang K, Wang H, et al. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis. PloS one, 2018;13(5):e0194463.
- 8. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658-64
- 9. Trillsch F, Mahner S, Woelber L, et al. Age-dependent differences in borderline ovarian tumours (borderline ovarian tumor) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROborderline ovarian tumor study. Ann Oncol. 2014;25:1320-7.
- 10. Turan G, Usta CS, Usta A, et al. "The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables." J Mol Hist 2014;4: 679-87.
